![Dicky To](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dicky To
Private Equity Investor bei
ORI Capital Investment Advisory Hong Kong Ltd.
Profil
Dicky To is currently a Partner at ORI Capital Investment Advisory Hong Kong Ltd. He previously worked as a Managing Director & Partner at RSM Hong Kong.
Mr. To completed his undergraduate degree at the University of Hong Kong.
Aktive Positionen von Dicky To
| Unternehmen | Position | Beginn |
|---|---|---|
ORI Capital Investment Advisory Hong Kong Ltd.
 ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital invests in companies located across the globe. The firm targets companies operating in the fields of biotech with a focus on diagnostics, drug delivery, and therapeutics. It participates in early-stage transactions. | Private Equity Investor | 01.04.2019 |
Ehemalige bekannte Positionen von Dicky To
| Unternehmen | Position | Ende |
|---|---|---|
RSM Hong Kong
 RSM Hong Kong Miscellaneous Commercial ServicesCommercial Services Provides accounting and consulting services | Corporate Officer/Principal | - |
Ausbildung von Dicky To
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
1
Beziehungen ersten Grades
3
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
RSM Hong Kong
RSM Hong Kong Miscellaneous Commercial ServicesCommercial Services Provides accounting and consulting services | Commercial Services |
University of Hong Kong
 University of Hong Kong Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital invests in companies located across the globe. The firm targets companies operating in the fields of biotech with a focus on diagnostics, drug delivery, and therapeutics. It participates in early-stage transactions. | Finance |
